Cargando…
Single-center evaluation of a next generation fully repositionable and retrievable transcatheter aortic valve replacement
BACKGROUND: The mechanically expandable Lotus Valve System is a fully repositionable and retrievable valve with an adaptive seal to minimize paravalvular leak (PVL). The aim of this study was to evaluate the short- and long-term safety and efficacy of the new device with focus on a new implantation...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6390309/ https://www.ncbi.nlm.nih.gov/pubmed/30808296 http://dx.doi.org/10.1186/s12872-019-1021-7 |
_version_ | 1783398116166205440 |
---|---|
author | Berntorp, Karolina Koul, Sasha Nozohoor, Shahab Harnek, Jan Bjursten, Henrik Götberg, Matthias |
author_facet | Berntorp, Karolina Koul, Sasha Nozohoor, Shahab Harnek, Jan Bjursten, Henrik Götberg, Matthias |
author_sort | Berntorp, Karolina |
collection | PubMed |
description | BACKGROUND: The mechanically expandable Lotus Valve System is a fully repositionable and retrievable valve with an adaptive seal to minimize paravalvular leak (PVL). The aim of this study was to evaluate the short- and long-term safety and efficacy of the new device with focus on a new implantation technique to reduce the need for a permanent pacemaker (PPM) post procedure. METHODS: We performed a prospective single-center, non-randomized evaluation of the Lotus Valve System. The first 100 consecutive Lotus Valve implantations were included in the analysis. Outcome was assessed according to VARC2-criteria. Postoperative pacemaker rates were assessed using the national pacemaker registry and electronic medical records. Mortality at 30 days and 12 months were acquired from the national population registry. RESULTS: Mean age was 82.7 ± 5.6 years, mean Euroscore I was 25.3 ± 14.5%, mean STS-score was 6.5 ± 4.1% and mean aortic valve area was 0.6 ± 0.1 cm(2). There were no cases of valve embolization, ectopic valve deployment or additional valve implantation. Device success according to the VARC2-criteria was 97%. The 30-day mortality rate was 3%. Two deaths occurred due to stroke and one due to a ventricular rupture. Major stroke rate was 2% and major vascular complication rate was 2%. The 12-month mortality rate was 14%. At discharge 87% of patients had no/trace PVL, 12% had mild PVL and one patient had a moderate PVL. A total of 13% received a new PPM post valve implantation. Among patients who did not have a PPM before the procedure, the PPM rate was 15.3%. CONCLUSIONS: This single-center evaluation of the Lotus Valve System demonstrated a good clinical outcome with a low mortality, in a high-risk population. Introduction of a new implantation technique resulted in lower PPM rates than previously reported without negatively affecting PVL. TRIAL REGISTRATION: Current Controlled Trials ISRCTN14952278, retrospectively registered 06/11/2017. |
format | Online Article Text |
id | pubmed-6390309 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-63903092019-03-19 Single-center evaluation of a next generation fully repositionable and retrievable transcatheter aortic valve replacement Berntorp, Karolina Koul, Sasha Nozohoor, Shahab Harnek, Jan Bjursten, Henrik Götberg, Matthias BMC Cardiovasc Disord Research Article BACKGROUND: The mechanically expandable Lotus Valve System is a fully repositionable and retrievable valve with an adaptive seal to minimize paravalvular leak (PVL). The aim of this study was to evaluate the short- and long-term safety and efficacy of the new device with focus on a new implantation technique to reduce the need for a permanent pacemaker (PPM) post procedure. METHODS: We performed a prospective single-center, non-randomized evaluation of the Lotus Valve System. The first 100 consecutive Lotus Valve implantations were included in the analysis. Outcome was assessed according to VARC2-criteria. Postoperative pacemaker rates were assessed using the national pacemaker registry and electronic medical records. Mortality at 30 days and 12 months were acquired from the national population registry. RESULTS: Mean age was 82.7 ± 5.6 years, mean Euroscore I was 25.3 ± 14.5%, mean STS-score was 6.5 ± 4.1% and mean aortic valve area was 0.6 ± 0.1 cm(2). There were no cases of valve embolization, ectopic valve deployment or additional valve implantation. Device success according to the VARC2-criteria was 97%. The 30-day mortality rate was 3%. Two deaths occurred due to stroke and one due to a ventricular rupture. Major stroke rate was 2% and major vascular complication rate was 2%. The 12-month mortality rate was 14%. At discharge 87% of patients had no/trace PVL, 12% had mild PVL and one patient had a moderate PVL. A total of 13% received a new PPM post valve implantation. Among patients who did not have a PPM before the procedure, the PPM rate was 15.3%. CONCLUSIONS: This single-center evaluation of the Lotus Valve System demonstrated a good clinical outcome with a low mortality, in a high-risk population. Introduction of a new implantation technique resulted in lower PPM rates than previously reported without negatively affecting PVL. TRIAL REGISTRATION: Current Controlled Trials ISRCTN14952278, retrospectively registered 06/11/2017. BioMed Central 2019-02-26 /pmc/articles/PMC6390309/ /pubmed/30808296 http://dx.doi.org/10.1186/s12872-019-1021-7 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Berntorp, Karolina Koul, Sasha Nozohoor, Shahab Harnek, Jan Bjursten, Henrik Götberg, Matthias Single-center evaluation of a next generation fully repositionable and retrievable transcatheter aortic valve replacement |
title | Single-center evaluation of a next generation fully repositionable and retrievable transcatheter aortic valve replacement |
title_full | Single-center evaluation of a next generation fully repositionable and retrievable transcatheter aortic valve replacement |
title_fullStr | Single-center evaluation of a next generation fully repositionable and retrievable transcatheter aortic valve replacement |
title_full_unstemmed | Single-center evaluation of a next generation fully repositionable and retrievable transcatheter aortic valve replacement |
title_short | Single-center evaluation of a next generation fully repositionable and retrievable transcatheter aortic valve replacement |
title_sort | single-center evaluation of a next generation fully repositionable and retrievable transcatheter aortic valve replacement |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6390309/ https://www.ncbi.nlm.nih.gov/pubmed/30808296 http://dx.doi.org/10.1186/s12872-019-1021-7 |
work_keys_str_mv | AT berntorpkarolina singlecenterevaluationofanextgenerationfullyrepositionableandretrievabletranscatheteraorticvalvereplacement AT koulsasha singlecenterevaluationofanextgenerationfullyrepositionableandretrievabletranscatheteraorticvalvereplacement AT nozohoorshahab singlecenterevaluationofanextgenerationfullyrepositionableandretrievabletranscatheteraorticvalvereplacement AT harnekjan singlecenterevaluationofanextgenerationfullyrepositionableandretrievabletranscatheteraorticvalvereplacement AT bjurstenhenrik singlecenterevaluationofanextgenerationfullyrepositionableandretrievabletranscatheteraorticvalvereplacement AT gotbergmatthias singlecenterevaluationofanextgenerationfullyrepositionableandretrievabletranscatheteraorticvalvereplacement |